Crossref
The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women
Pharmacognosy Communications · 17.07.2026 · 16 (3) · 157-158
DOI: 10.5530/pc.2026.3.18 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacognosy Communications, online erschienen am 17.07.2026. Verfasst von Ian Edwin Cock.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Cock, I. E. (2026). The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women. Pharmacognosy Communications, 16(3), 157-158. https://doi.org/10.5530/pc.2026.3.18
Vancouver
Cock IE. The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women. Pharmacognosy Communications. 2026;16(3):157-158. doi:10.5530/pc.2026.3.18
BibTeX
@article{Cock2026,
author = {Cock, Ian Edwin},
title = {The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women},
journal = {Pharmacognosy Communications},
year = {2026},
volume = {16},
number = {3},
pages = {157--158},
doi = {10.5530/pc.2026.3.18}
}
EUVIMED